Answers are grounded in this paper and cite their sources.
Binuclear dinitrosyl iron complexes show 90% tumor growth inhibition in a Lewis lung carcinoma model, implying a role of immunocompetent cells.
Binuclear dinitrosyl iron complexes with cysteine (B-DNIC-Cys), which are donors of nitrosonium cations (NO+), exhibit high antitumor activity when exposed to a formed tumor weighing 0.42 grams (12 days after transplantation), causing a 90% inhibition of tumor growth for 11 days and a 9.3-fold increase in the time of tumor mass doubling compared to the control (Lewis lung carcinoma). With early initiation of the complex administration − the next day after tumor transplantation – any noticeable effect on the tumor growth rate was not observed. It is assumed that the detected difference in the antitumor action of dinitrosyl iron complexes with cysteine depending on the tumor size is due to different ratios between the level of immunocompetent cells (macrophages) that selectively transfer these complexes and retain this ability, and the concentration of tumor cells that accept the complexes. With late initiation of the administration of dinitrosyl iron complexes with cysteine, this ratio increases due to a decrease in the number of tumor cells accessible to immunocompetent cells: it is limited to cells localized only in the peripheral (“superficial”) layer of the tumor.
No takes yet. Share an insight, caveat, or question.
Vanin Af (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: